BioWorld published the story on November 18, 2025, with Randy Osborne as the author.

Markets reacted to the news: Olema Pharmaceuticals’ stock surged about 167% to roughly $22.71, while Roche shares rose about 8% to around $48.29.

Access to full trial details was limited to subscribers or sign-ins on BioWorld, with full results not publicly presented at that time.

Context in BioWorld includes CERAN wrap framing and links to related topics, highlighting the broader breast cancer treatment landscape.

While full trial results had not been publicly released yet, findings were expected to be presented at an upcoming meeting.

Roche’s broader breast cancer portfolio, including Herceptin, Perjeta, Kadcyla, and Phesgo, as well as the approval activity around inavolisib with a related FDA-approved combination, underscores ongoing oncology strategy.

Giredestrant demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival when compared with standard-of-care endocrine therapy in the adjuvant setting at interim analysis.

RHHBY notes lidERA is the first Phase III SERD trial to show a significant adjuvant benefit, with interim data suggesting a positive trend in overall survival though maturity was limited at analysis.

The original article source is Zacks Investment Research, which also provided stock market context and related links.

Roche Genentech reported positive phase III lidERA results for giredestrant, a selective estrogen receptor degrader and complete estrogen receptor antagonist, as an adjuvant endocrine therapy in ER-positive, HER2-negative early breast cancer.

Olema’s lead candidate palazestrant, a complete ER antagonist and SERD, is in two Phase 3 trials (OPERA-01 and OPERA-02) with ongoing enrollment, contributing to stock momentum in Olema.

Context notes rising metastatic breast cancer diagnoses among younger women and links to screening gaps, lifestyle factors, and Covid-19 impact on diagnosis timing.